Previous close | 89.24 |
Open | 89.05 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 89.05 - 89.05 |
52-week range | 66.01 - 92.79 |
Volume | |
Avg. volume | 1 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
(Bloomberg) -- Bicara Therapeutics is working with Morgan Stanley on a US initial public offering, people familiar with the situation said, as the market for first-time share sales is showing signs of normalizing. Most Read from BloombergBiden Asks Donors to Stay Following Disastrous DebateBiden's Defiance Has Democrats Fearing They'll Lose White HouseCLOs Have Too Much Money and Are Running Out of Things to BuyJustice Department to Charge Boeing, Seeks Guilty Plea from PlanemakerSingapore Loses
Morgan Stanley hit with cash-sweep suit. Morgan Stanley pays an interest rate of as little as 0.01% on customers’ uninvested cash in its default bank sweep program. Morgan Stanley declined to comment on the case.
(Bloomberg) -- Ten major US and European banks, including Goldman Sachs Group Inc., JPMorgan Chase & Co. and BNP Paribas SA, plan to pay a combined $46 million to end a lengthy legal battle with pension plans that accused them of conspiring to block competitors in interest-rate swaps trading. Most Read from BloombergBiden’s Disastrous Debate Accelerates Doubts Over CandidacyBiden Struggles as He Spars With Trump on Economy: Debate TakeawaysDemocrats Question Replacing Biden: Here’s How It Could